Zhong Jeffrey, Jang Albert, Abuqayas Bashar, Basu Arnab, Benjamin David J, Bhatlapenumarthi Vineel, Bilen Mehmet Asim, Buch Dhvani, Chang Mark, Chin Erica, Darabi Sourat, Dhanikonda Nagendra, Ghatalia Pooja, Grigg Claud M, Grier Abby L, Jindal Tanya, Jung Joannah, Kilari Deepak, Kumar Hamsa L S, Lee Suzanna, Neelands Brittany, Pandya Chinmayi, Pawalek Jeff, Staggers Jaimee, Yildirim Ahmet, Zakharia Yousef, Zarrabi Kevin K, Zimmerman Michael, Sledge George, Spetzler David, Elliott Andrew, McKay Rana R, Barata Pedro C
Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
Division of Oncology, Holden Comprehensive Cancer Center, Iowa City, IA 52242, United States.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf135.
The REnal cancer consortium for Focused Investigation of Novel biomarkers and Expression (REFINE) consortium represents an important initiative in integrating clinical data with molecular sequencing in patients with advanced renal cell carcinoma (RCC) treated with immunotherapy-based approaches. By leveraging real-world evidence and genomic analysis, this consortium aims to explore putative predictive biomarkers with the potential to inform personalized treatment strategies. Findings from the REFINE database may further contribute to our understanding of disease courses of immunotherapy-based approaches for various molecular subtypes of RCC, associations of race and ethnicity with RCC treatment and outcomes with representation of patient populations underrepresented in clinical trials, and optimizing treatment sequencing.
用于新型生物标志物和表达聚焦研究的肾癌联盟（REFINE）代表了一项重要举措，即将临床数据与接受基于免疫疗法治疗的晚期肾细胞癌（RCC）患者的分子测序相结合。通过利用真实世界证据和基因组分析，该联盟旨在探索可能的预测性生物标志物，以指导个性化治疗策略。REFINE数据库的研究结果可能会进一步帮助我们了解基于免疫疗法治疗RCC各种分子亚型的疾病进程、种族与RCC治疗及结果的关联，以及临床试验中代表性不足的患者群体的情况，并优化治疗顺序。
